Citadel Advisors LLC Takes $44,000 Position in COLLPLANT HOLDI/S (NASDAQ:CLGN)

Citadel Advisors LLC purchased a new stake in COLLPLANT HOLDI/S (NASDAQ:CLGN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,119 shares of the company’s stock, valued at approximately $44,000.

A number of research analysts have recently weighed in on CLGN shares. ValuEngine upgraded COLLPLANT HOLDI/S from a “hold” rating to a “buy” rating in a research report on Monday, October 7th. Zacks Investment Research upgraded COLLPLANT HOLDI/S from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research report on Tuesday, October 1st. Finally, HC Wainwright set a $7.00 price target on COLLPLANT HOLDI/S and gave the company a “buy” rating in a research report on Friday, September 27th.

Shares of CLGN stock opened at $4.14 on Friday. COLLPLANT HOLDI/S has a fifty-two week low of $3.13 and a fifty-two week high of $8.73. The business has a fifty day simple moving average of $4.10 and a 200-day simple moving average of $4.64. The company has a debt-to-equity ratio of 1.65, a quick ratio of 0.81 and a current ratio of 1.10.



COLLPLANT HOLDI/S Profile

CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe.

Featured Story: High-Yield Dividend Stocks

Want to see what other hedge funds are holding CLGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for COLLPLANT HOLDI/S (NASDAQ:CLGN).

Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.